Erasca, Inc.

ERASSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1761918

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Operating Expenses	$179.6M	$141.5M	$247.4M	$124.9M	$109.3M
Operating Income (Loss)	-$179.6M	-$141.5M	-$247.4M	-$124.9M	-$109.3M
Nonoperating Income (Expense)	$17.9M	$16.5M	$4.6M	$2.1M	$7.6M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$161.7M	—	—	—	—
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$161.7M	-$125.0M	-$242.8M	-$122.8M	-$101.7M
Earnings Per Share, Basic	-$0.69	-$0.83	-$1.99	-$1.85	—
Earnings Per Share, Diluted	-$0.69	-$0.83	-$1.99	-$1.85	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$502.5M	$395.3M	$514.9M	$501.4M	$124.8M
Assets, Current	$308.8M	$320.7M	$444.5M	$420.0M	$120.0M
Cash and Cash Equivalents, at Carrying Value	$67.7M	$93.1M	$284.2M	$360.5M	$65.4M
Liabilities	$79.0M	$78.6M	$103.1M	$44.9M	$17.4M
Liabilities, Current	$31.4M	$26.2M	$48.7M	$26.2M	$13.7M
Accounts Payable, Current	$468.0K	$2.0M	$23.0M	$4.7M	$878.0K
Stockholders' Equity Attributable to Parent	$316.7M	$411.9M	$456.5M	-$114.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$109.4M	-$101.2M	-$103.3M	-$79.6M	-$32.7M
Net Cash Provided by (Used in) Investing Activities	-$156.6M	-$91.2M	-$71.1M	-$64.6M	-$71.2M
Net Cash Provided by (Used in) Financing Activities	$240.7M	$1.3M	$98.1M	$439.4M	$140.0M
Payments to Acquire Property, Plant, and Equipment	$60.0K	$1.8M	$14.6M	$11.2M	$947.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)